Venetoclax, Azacitidine

DRUG2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University

Conditions

Acute Myeloid LeukemiaMeasurable DiseaseRecruitingT-cell Acute Lymphoblastic Leukemia

Phase 2

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

TerminatedNCT05361057

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Myeloid Leukemia, Measurable Disease

Start: 2022-06-29End: 2024-01-23Updated: 2025-12-05

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

RecruitingNCT05376111

The First Affiliated Hospital of Soochow UniversityRecruiting, T-cell Acute Lymphoblastic Leukemia

Start: 2022-04-01End: 2026-12-01Target: 28Updated: 2026-03-19